Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:50933 |
Name | ovarian serous carcinoma |
Definition | An ovarian carcinoma that has_material_basis_in the lining of the ovary and produces a serum-like fluid. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer ovarian cancer ovary epithelial cancer malignant ovarian surface epithelial-stromal neoplasm ovarian carcinoma ovarian serous carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
TP53 mutant | thioureidobutyronitrile | ovarian serous carcinoma | sensitive | detail... |
MAP2K1 Q56_V60del | Selumetinib | ovarian serous carcinoma | predicted - sensitive | detail... |
BRAF V600E | Lifirafenib | ovarian serous carcinoma | predicted - sensitive | detail... |
BRAF V600E | Trametinib | ovarian serous carcinoma | predicted - sensitive | detail... |
EML4 - ALK | Alectinib | ovarian serous carcinoma | predicted - sensitive | detail... |
BRAF V600E | Dabrafenib + Trametinib | ovarian serous carcinoma | predicted - sensitive | detail... |
BRAF V600E | Binimetinib + Encorafenib | ovarian serous carcinoma | predicted - sensitive | detail... |
MAP2K1 F129L | Trametinib | ovarian serous carcinoma | resistant | detail... |
MAP2K1 F129L | Selumetinib | ovarian serous carcinoma | resistant | detail... |
MAP2K1 F129L | Binimetinib | ovarian serous carcinoma | resistant | detail... |
MAP2K1 F129L | Refametinib | ovarian serous carcinoma | resistant | detail... |
BRAF V600E | BGB3245 | ovarian serous carcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02208375 | Phase Ib/II | Capivasertib + Olaparib Olaparib + Vistusertib | mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian | Active, not recruiting | USA | 0 |
NCT02364713 | Phase II | Pegylated liposomal doxorubicin Bevacizumab + Topotecan Topotecan Paclitaxel MV-NIS Bevacizumab + Paclitaxel Bevacizumab + Pegylated liposomal doxorubicin Gemcitabine | MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer | Active, not recruiting | USA | 0 |
NCT02446600 | Phase III | Cediranib + Olaparib Olaparib Carboplatin + Gemcitabine + Paclitaxel + Pegylated liposomal doxorubicin | Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Active, not recruiting | USA | CAN | 2 |
NCT02540291 | Phase I | E7046 | Study of E7046 in Subjects With Selected Advanced Malignancies | Terminated | USA | FRA | 0 |
NCT02759588 | Phase Ib/II | GL-ONC1 | GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent Ovarian Cancer | Completed | USA | 0 |
NCT02898207 | Phase I | Olaparib + Onalespib | Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer | Completed | USA | 0 |
NCT02983799 | Phase II | Olaparib | Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status | Completed | USA | CAN | 0 |
NCT03042702 | Phase II | thioureidobutyronitrile | A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer | Completed | USA | 0 |
NCT03054298 | Phase I | HuCART-meso cells Cyclophosphamide | CAR T Cells in Mesothelin Expressing Cancers | Recruiting | USA | 0 |
NCT03096054 | Phase I | LY3143921 | A CR-UK Phase I Trial of LY3143921 | Active, not recruiting | GBR | 0 |
NCT03134638 | Phase I | Carboplatin + SY-1365 SY-1365 Fulvestrant + SY-1365 | A Study of SY-1365 in Adult Patients With Advanced Solid Tumors | Terminated | USA | FRA | CAN | 0 |
NCT03144661 | Phase I | INCB062079 | An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies | Terminated | USA | BEL | 0 |
NCT03205176 | Phase I | AZD5153 | Phase I Study of AZD5153 in Patients With Relapsed or Refractory Solid Tumors and Lymphomas | Completed | USA | CAN | 0 |
NCT03278717 | Phase III | Olaparib Cediranib + Olaparib | Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients (ICON9) | Recruiting | GBR | CAN | AUS | 1 |
NCT03363867 | Phase II | Atezolizumab + Bevacizumab + Cobimetinib | BEACON - ABC in Recurrent Platinum Resistant HGSOC (BEACON) | Active, not recruiting | AUS | 0 |
NCT03402841 | Phase III | Olaparib | Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients (OPINION) | Completed | ITA | GBR | ESP | CAN | BEL | AUT | 12 |
NCT03414047 | Phase II | Prexasertib | A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer | Completed | USA | ITA | GBR | ESP | BEL | AUS | 2 |
NCT03462212 | Phase Ib/II | Bevacizumab + Carboplatin + Paclitaxel + Rucaparib Carboplatin + Paclitaxel + Rucaparib Bevacizumab + Carboplatin + Paclitaxel | Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination (MITO25) | Recruiting | ITA | 0 |
NCT03462342 | Phase II | Ceralasertib + Olaparib | Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer (CAPRI) | Recruiting | USA | 0 |
NCT03531645 | Phase II | Fulvestrant + Palbociclib | Fulvestrant Plus Palbociclib in Women With Advanced Low Grade Serous Carcinoma | Active, not recruiting | USA | 0 |
NCT03587311 | Phase II | Anetumab ravtansine + Bevacizumab Bevacizumab + Paclitaxel | Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Participants With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Active, not recruiting | USA | CAN | 0 |
NCT03598270 | Phase III | Carboplatin + Gemcitabine Niraparib Carboplatin + Pegylated liposomal doxorubicin Atezolizumab + Carboplatin + Pegylated liposomal doxorubicin Atezolizumab + Carboplatin + Gemcitabine Atezolizumab + Carboplatin + Paclitaxel Carboplatin + Paclitaxel Atezolizumab + Niraparib | Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer (ANITA) | Active, not recruiting | ITA | FRA | ESP | DEU | BEL | 0 |
NCT03602859 | Phase III | Dostarlimab-gxly + Niraparib Niraparib | A Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | 11 |
NCT03673124 | Phase II | Letrozole + Ribociclib | Ribociclib and Letrozole Treatment in Ovarian Cancer | Active, not recruiting | USA | 0 |
NCT03695380 | Phase I | Atezolizumab + Cobimetinib + Niraparib Cobimetinib + Niraparib | A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer | Completed | USA | ITA | ESP | 0 |
NCT03840200 | Phase Ib/II | Ipatasertib + Rucaparib | A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer. | Completed | USA | ITA | ESP | AUS | 1 |
NCT03909152 | Phase II | Onapristone Anastrozole + Onapristone | A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone | Active, not recruiting | USA | 0 |
NCT03926936 | Phase II | Fulvestrant | FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study (FUCHSia) | Recruiting | BEL | 0 |
NCT03955471 | Phase II | Dostarlimab-gxly + Niraparib | Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer (MOONSTONE) | Terminated | USA | 0 |
NCT04034927 | Phase II | Olaparib Olaparib + Tremelimumab | Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer | Active, not recruiting | USA | 0 |
NCT04092270 | Phase I | Pegylated liposomal doxorubicin + Peposertib | A Study Combining the M3814 Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer Patients | Recruiting | USA | 0 |
NCT04095364 | Phase III | Carboplatin + Letrozole + Paclitaxel Letrozole | Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian or Primary Peritoneal Cancer | Recruiting | USA | CAN | 1 |
NCT04205227 | Phase Ib/II | ENB003 + Pembrolizumab | ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors | Active, not recruiting | USA | AUS | 0 |
NCT04209855 | Phase III | Paclitaxel Pegylated liposomal doxorubicin Mirvetuximab Soravtansine Topotecan | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (MIRASOL) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 12 |
NCT04293094 | Phase I | AMG 650 | Study of AMG 650 in Adult Participants With Advanced Solid Tumors | Completed | USA | ITA | ESP | CAN | BEL | AUS | 1 |
NCT04296890 | Phase III | Mirvetuximab Soravtansine | A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression | Completed | USA | ITA | ESP | DEU | BEL | AUS | 5 |
NCT04315233 | Phase I | Belinostat + Ribociclib | Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics (CHARGE) | Recruiting | USA | 0 |
NCT04374630 | Phase II | Afuresertib + Paclitaxel Paclitaxel | Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian (PROFECTA-II) | Active, not recruiting | USA | 1 |
NCT04421963 | Phase III | Olaparib | Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib (ROSY-O) | Enrolling by invitation | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | 16 |
NCT04460807 | Phase III | Exemestane | Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer (EXPERT) | Unknown status | ITA | 0 |
NCT04510584 | Phase II | Atezolizumab + Bevacizumab | Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer | Withdrawn | CAN | 0 |
NCT04575961 | Phase II | Carboplatin + Pegylated liposomal doxorubicin + Pembrolizumab Carboplatin + Gemcitabine + Pembrolizumab | Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer (PERCEPTION) | Recruiting | DEU | 0 |
NCT04586335 | Phase I | CYH33 + Olaparib | Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. | Recruiting | USA | AUS | 1 |
NCT04625270 | Phase II | Defactinib + RO5126766 RO5126766 | A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation (RAMP 201) | Recruiting | USA | ITA | GBR | FRA | ESP | CAN | BEL | 0 |
NCT04657068 | Phase Ib/II | ART0380 + Gemcitabine ART0380 Gemcitabine | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | Recruiting | USA | GBR | ESP | 0 |
NCT04669002 | Phase II | NLG207 + Olaparib | EP0057 in Combination With Olaparib in Advanced Ovarian Cancer | Completed | USA | GBR | 1 |
NCT04703920 | Phase I | Belinostat + Talazoparib | Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer | Recruiting | USA | 0 |
NCT04729387 | Phase III | Pegylated liposomal doxorubicin Paclitaxel Alpelisib + Olaparib | Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 16 |
NCT04814875 | Phase Ib/II | ATX101 + Carboplatin + Pegylated liposomal doxorubicin | A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy | Recruiting | AUS | 0 |
NCT04893551 | Phase I | BGB149 | A Study of Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Participants | Terminated | GBR | 3 |
NCT04918186 | Phase II | BA3021 + Durvalumab Durvalumab + Mecbotamab Vedotin | Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (IPROC) | Recruiting | USA | CAN | 0 |
NCT04931342 | Phase II | Cobimetinib Ado-trastuzumab emtansine Ipatasertib + Paclitaxel Atezolizumab + Bevacizumab | A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 5 |
NCT05039801 | Phase I | Bevacizumab + IACS-6274 + Paclitaxel IACS-6274 | IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05057715 | Phase I | HuCART-meso cells + VCN-01 | huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer | Recruiting | USA | 0 |
NCT05065021 | Phase II | Bevacizumab + Dostarlimab-gxly + Niraparib Bevacizumab + Niraparib Bevacizumab + Dostarlimab-gxly + Paclitaxel | Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor | Recruiting | CAN | 0 |
NCT05113368 | Phase II | Fulvestrant + Regorafenib | Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer | Not yet recruiting | USA | 0 |
NCT05114421 | Phase II | Lenvatinib + Pembrolizumab | Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients | Recruiting | USA | 0 |
NCT05123482 | Phase Ib/II | AZD8205 | First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies | Recruiting | USA | GBR | ESP | CAN | BEL | AUS | 7 |
NCT05183984 | Phase II | Carboplatin + Niraparib + Paclitaxel Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Niraparib | Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer (NIRVANA-1) | Recruiting | FRA | 1 |
NCT05229900 | Phase I | SGN-ALPV | A Study of SGN-ALPV in Advanced Solid Tumors | Recruiting | USA | GBR | ESP | CAN | 1 |
NCT05257408 | Phase III | Nab-paclitaxel Nab-paclitaxel + Relacorilant | Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer | Recruiting | USA | ITA | FRA | ESP | CAN | BEL | 4 |
NCT05295589 | Phase II | Topotecan Pegylated liposomal doxorubicin Copanlisib + Olaparib Paclitaxel | Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy | Withdrawn | USA | 0 |
NCT05329532 | Phase Ib/II | Modi-1 Modi-1 + Pembrolizumab | Modi-1 in Breast, Head and Neck, Ovarian, or Renal Cancer (ModiFY) | Recruiting | GBR | 0 |
NCT05358639 | Phase I | Navitoclax + Olaparib | Combination of Olaparib and Navitoclax in Women With HGSC and TNBC | Recruiting | CAN | 0 |
NCT05446298 | Phase II | ONC-392 + Pembrolizumab | ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer (PRESERVE-004) | Recruiting | USA | 0 |
NCT05446870 | Phase II | Bevacizumab + Docetaxel + MK-4830 + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + MK-4830 + Paclitaxel + Pembrolizumab Bevacizumab + Docetaxel + Paclitaxel + Pembrolizumab Docetaxel + MK-4830 + Paclitaxel + Pembrolizumab Carboplatin + MK-4830 + Paclitaxel + Pembrolizumab | Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002) | Recruiting | USA | ITA | ESP | CAN | BEL | 6 |
NCT05465941 | Phase II | PLX038 | PLX038 for the Treatment of Patients With Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | Suspended | USA | 0 |
NCT05498597 | Phase I | AMT-151 | AMT-151 in Patients With Selected Advanced Solid Tumours | Recruiting | AUS | 0 |
NCT05544929 | Phase I | KFA115 + Tislelizumab KFA115 | A Study of Safety and Efficacy of KFA115 Alone and KFA115 in Combination With Tislelizumab in Patients With Select Advanced Cancers | Recruiting | USA | CAN | 3 |
NCT05601700 | Phase III | Carboplatin + Paclitaxel Letrozole | Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial) (LEPRE) | Recruiting | ITA | 0 |
NCT05605509 | Phase II | Fluorouracil + Irinotecan + Leucovorin + RP-6306 RP-6306 + Trastuzumab Gemcitabine + RP-6306 | RP-6306 in Patients With Advanced Cancer | Recruiting | CAN | 0 |
NCT05700669 | Phase Ib/II | AsiDNA + Olaparib | Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors | Recruiting | USA | 0 |
NCT05841563 | Phase I | PM54 | Clinical Trial of PM54 in Advance Solid Tumors Patients. | Recruiting | USA | ESP | BEL | 0 |
NCT05870748 | Phase II | Luveltamab Tazevibulin Luveltamab Tazevibulin + Pegfilgrastim | REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 | Recruiting | AUS | 0 |
NCT05872204 | Phase II | Abemaciclib + Letrozole | Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer (ALEPRO) | Not yet recruiting | BEL | 0 |
NCT05920798 | Phase Ib/II | FR alpha peptide vaccine + Pembrolizumab | A Study of FRaDCs for Ovarian Cancer | Not yet recruiting | USA | 0 |
NCT05950464 | Phase I | M1774 + ZEN-3694 | Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer | Recruiting | 0 | |
NCT05961124 | Phase II | Niraparib | Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer | Not yet recruiting | CAN | 0 |
NCT05998135 | Phase II | Atovaquone | Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer | Not yet recruiting | USA | 0 |